Skip to content
value.today
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

🇺🇸 Waltham, Massachusetts, USABiotechnologyFounded 2020
Total raised
$145 M
2 rounds on record
Latest round
$95 M
Feb 2021
First round on record
Jan 2021
Today
Went public
See the company page

Xilio Therapeutics, Inc. is listed today as Xilio Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Xilio Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$95 MNo. 2$50 to $250 million

Xilio Therapeutics, Inc.: Raise no. 2, Feb 2021

Investors in this round

17 investors had bought by the notice of Feb 26, 2021: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$95 M of $95 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph Farmer · Executive Officer
  • Rene Russo · Executive Officer, Director
  • Timothy Clackson · Executive Officer
  • Andrew Hack · Director
  • Daniel Curran · Director
  • Daniel Lynch · Director
  • David Gardner · Director
  • David Grayzel · Director
  • Michael Ross · Director
  • Paul Clancy · Director
  • Rachel Humphrey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph Farmer, Chief Operating Officer. Newest notice filed Feb 26, 2021. Read the notice at the SEC.

equitySEC
Jan 2021$50 MNo. 1$50 to $250 million

Xilio Therapeutics, Inc.: Raise no. 1, Jan 2021

Investors in this round

16 investors had bought by the notice of Jan 21, 2021: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph Farmer · Executive Officer
  • Rene Russo · Executive Officer, Director
  • Timothy Clackson · Executive Officer
  • Daniel Curran · Director
  • Daniel Lynch · Director
  • David Grayzel · Director
  • Michael Ross · Director
  • Nancy Hong · Director
  • Paul Clancy · Director
  • Peter Dudek · Director
  • Rachel Humphrey · Director
  • Robert Weisskoff · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph Farmer, Chief Operating Officer. Newest notice filed Jan 21, 2021. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Xilio Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).

    SEC Form D · Feb 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2021

Products and services#

No products or services of Xilio Therapeutics, Inc. are on record.

Investors#

No investor of Xilio Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding Xilio Therapeutics, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Xilio Therapeutics, Inc.
NameRoleNamed in
Joseph FarmerExecutive officerFeb 2021
Rene RussoExecutive officerFeb 2021
Timothy ClacksonExecutive officerFeb 2021
Andrew HackDirectorFeb 2021
Daniel CurranDirectorFeb 2021
Daniel LynchDirectorFeb 2021
David GardnerDirectorFeb 2021
David GrayzelDirectorFeb 2021
Michael RossDirectorFeb 2021
Paul ClancyDirectorFeb 2021
Rachel HumphreyDirectorFeb 2021
Rene RussoDirectorFeb 2021
Nancy HongDirectorJan 2021
Peter DudekDirectorJan 2021
Robert WeisskoffDirectorJan 2021

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.